<?xml version="1.0" encoding="UTF-8"?>
<p id="p0120">The limitations of current management of COVID-19 are many, but the adverse events and the cost-effectiveness is most important (
 <xref rid="bib38" ref-type="bibr">38</xref>). Any drug that was suggested had a lot of economic and managerial impact on supply and demand apart from the therapeutic efficacy potency and toxicity. In this view, we propose that the shortlisted drugs in this study will have a higher ratio of benefits and can be further studied and repurposed in clinical trials.
</p>
